Literature DB >> 31093888

Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions.

Prathibha Surapaneni1, Robyn M Scherber2.   

Abstract

PURPOSE OF REVIEW: Myeloproliferative neoplasms (MPNs) have a high symptom burden that affects functional status, emotional well-being, and quality of life for patients. Symptom control continues to be a challenging therapeutic goal despite available pharmacologic interventions. The goal of this review is to detail recent efforts that have focused on non-pharmacologic interventions, such as wholistic or integrative medicine, as an adjunctive method to alter symptom burden in this population. RECENT
FINDINGS: We discuss the ongoing physical, nutritional, and psychological interventional efforts which represent promising non-traditional interventions to date to help reduce symptom in MPN patients. In this article, we highlight the early promising data and importance of these various non-pharmacological interventions to dampen symptom burden and reduce disease-related inflammation. Nonpharmacologic interventions represent promising therapeutic strategies to alter traditional MPN treatment paradigms and improve MPN patient care.

Entities:  

Keywords:  Chronic inflammation; Hematopoietic stem cells; Integrative medicine; Myeloproliferative neoplasms; Non-pharmacologic interventions; Quality of life; Symptom burden

Mesh:

Year:  2019        PMID: 31093888     DOI: 10.1007/s11899-019-00516-w

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  24 in total

Review 1.  Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.

Authors:  Ruben A Mesa; Robyn M Scherber; Holly L Geyer
Journal:  Leuk Lymphoma       Date:  2015-03-17

2.  The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

Authors:  Robyn Scherber; Amylou C Dueck; Peter Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Francesco Passamonti; Bjorn Andreasson; Maria L Ferarri; Alessandro Rambaldi; Jan Samuelsson; Gunnar Birgegard; Ayalew Tefferi; Claire N Harrison; Deepti Radia; Ruben A Mesa
Journal:  Blood       Date:  2011-05-02       Impact factor: 22.113

3.  Acceptance and commitment therapy program for distressed adults with a primary brain tumor: a case series study.

Authors:  Maria Kangas; Skye McDonald; Janet R Williams; Robert I Smee
Journal:  Support Care Cancer       Date:  2015-06-18       Impact factor: 3.603

Review 4.  Therapy for myeloproliferative neoplasms: when, which agent, and how?

Authors:  Holly L Geyer; Ruben A Mesa
Journal:  Blood       Date:  2014-12-04       Impact factor: 22.113

5.  The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

Authors:  Ruben A Mesa; Joyce Niblack; Martha Wadleigh; Srdan Verstovsek; John Camoriano; Sunni Barnes; Angelina D Tan; Pamela J Atherton; Jeff A Sloan; Ayalew Tefferi
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

6.  Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.

Authors:  Robyn M Emanuel; Amylou C Dueck; Holly L Geyer; Jean-Jacques Kiladjian; Stefanie Slot; Sonja Zweegman; Peter A W te Boekhorst; Suzan Commandeur; Harry C Schouten; Federico Sackmann; Ana Kerguelen Fuentes; Dolores Hernández-Maraver; Heike L Pahl; Martin Griesshammer; Frank Stegelmann; Konstanze Doehner; Thomas Lehmann; Karin Bonatz; Andreas Reiter; Francoise Boyer; Gabriel Etienne; Jean-Christophe Ianotto; Dana Ranta; Lydia Roy; Jean-Yves Cahn; Claire N Harrison; Deepti Radia; Pablo Muxi; Norman Maldonado; Carlos Besses; Francisco Cervantes; Peter L Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Francesco Passamonti; Bjorn Andreasson; Maria L Ferrari; Maria L Ferarri; Alessandro Rambaldi; Jan Samuelsson; Gunnar Birgegard; Ayalew Tefferi; Ruben A Mesa
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

7.  Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study.

Authors:  Panagiota N Mitrou; Victor Kipnis; Anne C M Thiébaut; Jill Reedy; Amy F Subar; Elisabet Wirfält; Andrew Flood; Traci Mouw; Albert R Hollenbeck; Michael F Leitzmann; Arthur Schatzkin
Journal:  Arch Intern Med       Date:  2007-12-10

8.  Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study.

Authors:  Christina Chrysohoou; Demosthenes B Panagiotakos; Christos Pitsavos; Undurti N Das; Christodoulos Stefanadis
Journal:  J Am Coll Cardiol       Date:  2004-07-07       Impact factor: 24.094

9.  A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.

Authors:  C Marty; C Lacout; N Droin; J-P Le Couédic; V Ribrag; E Solary; W Vainchenker; J-L Villeval; I Plo
Journal:  Leukemia       Date:  2013-04-05       Impact factor: 11.528

Review 10.  Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.

Authors:  Holly L Geyer; Amylou C Dueck; Robyn M Scherber; Ruben A Mesa
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711

View more
  4 in total

Review 1.  Advancing Effective Clinical Trial Designs for Myelofibrosis.

Authors:  Heidi E Kosiorek; Amylou C Dueck
Journal:  Hematol Oncol Clin North Am       Date:  2021-04       Impact factor: 3.722

2.  Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study.

Authors:  Hninyee Win; Samantha Russell; Betsy C Wertheim; Victoria Maizes; Robert Crocker; Audrey J Brooks; Ruben Mesa; Jennifer Huberty; Holly Geyer; Ryan Eckert; Ashley Larsen; Krisstina Gowin
Journal:  JMIR Form Res       Date:  2022-03-31

Review 3.  Host-related factors and cancer: Malnutrition and non-Hodgkin lymphoma.

Authors:  Salvatrice Mancuso; Marta Mattana; Marco Santoro; Melania Carlisi; Silvio Buscemi; Sergio Siragusa
Journal:  Hematol Oncol       Date:  2022-04-18       Impact factor: 4.850

4.  The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms.

Authors:  Krisstina Gowin; Blake T Langlais; Heidi E Kosiorek; Amylou Dueck; Denise Millstine; Jennifer Huberty; Ryan Eckert; Ruben A Mesa
Journal:  Cancer Med       Date:  2020-11-03       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.